Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928907 | PMC |
| http://dx.doi.org/10.1111/pai.70067 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bone marrow mastocytosis associated with primary cutaneous follicle center lymphoma: an unusual case report.
Ann Hematol
September 2025
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
In a subset of patients with systemic mastocytosis (SM), an associated hematologic neoplasm (AHN) is identified. Most AHN are myeloid neoplasms, whereas lymphoid neoplasms are uncommon. We report on a 70-year-old female patient with bone marrow mastocytosis (BMM) associated with primary cutaneous follicle center lymphoma (PCFCL).
View Article and Find Full Text PDFReal-world characteristics of systemic mastocytosis in Romania: insights from a reference-center-based descriptive study.
J Med Life
July 2025
Department of Dermatology and Allergology, Elias Emergency University Hospital, Bucharest, Romania.
Systemic mastocytosis (SM) is a rare clonal mast cell disease characterized by heterogeneous clinical presentations and molecular features that vary across different regions; however, data from Central-Eastern Europe remain limited. This study aimed to describe the demographic, clinical, laboratory, and molecular characteristics of Romanian adults diagnosed with SM and followed at the national reference center for mast cell disorders in Bucharest, while also exploring real-world management patterns and outcomes. We conducted a retrospective observational study including 162 adult patients evaluated between January 2006 and March 2025 who met the 2022 World Health Organization criteria for SM.
View Article and Find Full Text PDFIdiopathic Anaphylaxis Grand Rounds.
J Allergy Clin Immunol Pract
August 2025
Department of Medicine, Division of Allergy and Immunology, University of Michigan, Ann Arbor, Michigan, USA.
Idiopathic anaphylaxis (IA) refers to recurrent, life-threatening hypersensitivity reactions without identifiable triggers, representing a diagnostic and therapeutic challenge. We describe a 17-year-old girl presenting with recurrent episodes of flushing, pruritus, and respiratory symptoms, without consistent allergen exposure or cofactor involvement. Evaluation revealed elevated acute tryptase levels with a normal baseline, negative skin testing, and negative alpha-gal and KIT mutation analysis.
View Article and Find Full Text PDFOral Cephalosporin-Induced Anaphylaxis Presenting With Severe Tachycardia: A Case of Microdosed Epinephrine Over Standard Protocols.
Cureus
July 2025
Internal Medicine, Fortis International Hospital Rajajinagar, Bengaluru, IND.
Anaphylaxis is a severe, rapidly progressing hypersensitivity reaction that requires prompt recognition and administration of intramuscular epinephrine. While guidelines recommend fixed-dose intramuscular epinephrine regardless of heart rate or blood pressure, there are situations where this approach may carry risks. We present the case of a 27-year-old patient with no prior comorbidities, including asthma, allergies, or cardiovascular conditions, who developed sudden breathlessness, generalized urticaria, and swelling of the face and lips shortly after taking oral cefpodoxime, a third-generation cephalosporin, prescribed for a febrile illness at a local hospital.
View Article and Find Full Text PDFSafety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Commercially-insured individuals aged 6 months through 64 years: Self-controlled case series analyses.
Vaccine
August 2025
Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, U.S. Food & Drug Administration, 10903 New Hampshire Ave., Building 71, Silver Spring, MD 20993, United States. Electronic address:
Background: Influenza vaccines are reformulated annually to target expected virus strains for the upcoming season. Although the safety of seasonal influenza vaccines is well-established, active safety surveillance of reformulated vaccines is essential to assess occurrence of potential health outcomes among vaccinated individuals. This study evaluated the safety of the 2023-2024 influenza vaccines among U.
View Article and Find Full Text PDF